Alexion gets fast-track FDA review for drug Soliris
14th Nov 2006, 16:49 GMT
The U.S. Food and Drug Administration has accepted an application from Alexion Pharmaceuticals Inc. for blood-disorder drug Soliris and has designated the submission for review within the next six months, according to the Cheshire, Conn.-based company.
Alexion gets fast-track FDA review for drug Soliris related news:
- Alexion Gets Priority Review on Soliris — Bio-Technology News from StratCenter.com
- FDA Grants Priority Review for Soliris BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria — StratWire - Business of Healthcare NewsFeed
- Alexion's Soliris granted priority review — United Press International - Health Business
- Alexion Blood Disorder Treatment Granted Priority Review — RedOrbit News - Health
- ChemGenex's CML drug on fast-track — United Press International - Health Business
- FDA Grants Priority Review for Soliris(TM) (eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria — PR Newswire: All Releases
- FDA Extends Novartis Drug Review — WSJ.com: What's News Europe
- FDA Urges Caution on Flu Drug — WSJ.com: What's News US
- Review of Sanofi Drug Is Sought — WSJ.com: US Business
- FDA Review on Novartis Galvus Extended — Government/ Industry Regulation News from StratCenter.com
Latest news from bizjournals.com Health Care:Pharmaceuticals headlines:
- Spectrum Pharmaceuticals gets $5M milestone payment, settles with GlaxoSmithKline
- Corautus Genetics chips at Q3 loss
- Spherix hoping to brush its sweet tooth
- Auxilium added to NASDAQ's biotech index
- CombinatoRx reports revenue boost
- InnoCentive identifies a new CEO
- Digene names new CEO
- Dynamic Health dips into the red
- Sigma-Aldrich elects Paul to board
- CollaGenex to net $43M from stock sale